{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonia+Atrophica", "query": { "condition": "Myotonia Atrophica" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 43, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonia+Atrophica&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T03:52:08.668Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04886518", "title": "Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myotonic Dystrophy 1", "Excessive Daytime Sleepiness" ], "interventions": [ { "name": "Pitolisant Oral Tablet", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harmony Biosciences Management, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2021-06-28", "completion_date": "2024-10-31", "has_results": true, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 11, "location_summary": "Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04886518" }, { "nct_id": "NCT02398786", "title": "Myotonic Dystrophy Family Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy", "Congenital Myotonic Dystrophy", "Myotonic Dystrophy 1", "Myotonic Dystrophy 2", "Dystrophia Myotonica", "Dystrophia Myotonica 1", "Dystrophia Myotonica 2", "Myotonia Dystrophica", "Myotonic Dystrophy, Congenital", "Myotonic Myopathy, Proximal", "PROMM (Proximal Myotonic Myopathy)", "Proximal Myotonic Myopathy", "Steinert Disease", "Steinert Myotonic Dystrophy", "Steinert's Disease", "Myotonia Atrophica" ], "interventions": [ { "name": "Patient-entered data", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Myotonic Dystrophy Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 3500, "start_date": "2013-02", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02398786" }, { "nct_id": "NCT07630389", "title": "Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy Type 1", "Congenital DM1", "Juvenile DM1", "Childhood DM1" ], "interventions": [], "intervention_types": [], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Years to 17 Years" }, "enrollment_count": 100, "start_date": "2023-11-13", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630389" }, { "nct_id": "NCT01931644", "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "All Diagnosed Health Conditions", "ADD/ADHD", "Alopecia Areata", "Ankylosing Spondylitis", "Asthma", "Atopic Dermatitis Eczema", "Beta Thalassemia", "Bipolar Disorder", "Breast Cancer", "Celiac Disease", "Cervical Cancer", "Chronic Inflammatory Demyelinating Polyneuropathy", "Chronic Kidney Diseases", "Chronic Obstructive Pulmonary Disease", "Colon Cancer", "Colorectal Cancer", "Crohn's Disease", "Cystic Fibrosis", "Depression", "Diabetes Mellitus", "Duchenne Muscular Dystrophy", "Endometriosis", "Epilepsy", "Facioscapulohumeral Muscular Dystrophy", "G6PD Deficiency", "General Anxiety Disorder", "Hepatitis B", "Hereditary Hemorrhagic Telangiectasia", "HIV/AIDS", "Human Papilloma Virus", "Huntington's Disease", "Idiopathic Thrombocytopenic Purpura", "Insomnia", "Kidney Cancer", "Leukemia", "Lung Cancer", "Lupus Nephritis", "Lymphoma", "Melanoma", "Multiple Myeloma", "Multiple Sclerosis", "Myositis", "Myotonic Dystrophy", "Ovarian Cancer", "Pancreatic Cancer", "Parkinson's Disease", "Polycystic Kidney Diseases", "Prostate Cancer", "Psoriasis", "Psoriatic Arthritis", "Rosacea", "Scleroderma", "Sickle Cell Anemia", "Sickle Cell Trait", "Sjogren's Syndrome", "Skin Cancer", "Spinal Muscular Atrophy", "Systemic Lupus Erythematosus", "Thrombotic Thrombocytopenic Purpura", "Trisomy 21", "Ulcerative Colitis" ], "interventions": [], "intervention_types": [], "sponsor": "Sanguine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17667, "start_date": "2013-07", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931644" }, { "nct_id": "NCT06204809", "title": "Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myotonic Dystrophy 1" ], "interventions": [ { "name": "PGN-EDODM1 for infusion", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "PepGen Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2023-12-12", "completion_date": "2025-10-28", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 7, "location_summary": "Irvine, California • Palo Alto, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06204809" }, { "nct_id": "NCT02251457", "title": "Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myotonia Congenita", "Paramyotonia Congenita", "Myotonic Dystrophy 1" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 35, "start_date": "2014-08", "completion_date": "2017-12-18", "has_results": false, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02251457" }, { "nct_id": "NCT07362875", "title": "Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2025-05-15", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07362875" }, { "nct_id": "NCT06089018", "title": "Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy 1" ], "interventions": [], "intervention_types": [], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "12 Years to 90 Years" }, "enrollment_count": 125, "start_date": "2022-09-10", "completion_date": "2024-09-10", "has_results": false, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06089018" }, { "nct_id": "NCT05479981", "title": "Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DM1", "Muscular Dystrophies", "Myotonic Dystrophy", "Myotonic Dystrophy 1", "Myotonic Disorders", "Muscular Disorders, Atrophic", "Muscular Diseases", "Musculoskeletal Diseases", "Neuromuscular Diseases", "Nervous System Diseases", "Genetic Diseases, Inborn", "Heredodegenerative Disorders, Nervous System", "Neurodegenerative Diseases" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "AOC 1001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 37, "start_date": "2022-08-04", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 8, "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479981" }, { "nct_id": "NCT05004129", "title": "Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Congenital Myotonic Dystrophy" ], "interventions": [ { "name": "Tideglusib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AMO Pharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "6 Years to 45 Years" }, "enrollment_count": 76, "start_date": "2021-08-23", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-07-23T03:52:08.668Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05004129" } ] }